Sunday, April 23, 2006

THE NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)
THE NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK (CTN)

“Treating People with Dignity and Evidence Based Medicine: Emerging Research Findings on Buprenorphine, Hepatitis C and Prescription Drug Addiction”

TIME: 8:30 AM – 5:00 PM

8:30 AM – 8:45 AM Registration and Continental Breakfast

Session Chair: Betty Tai, PhD, Center for the Clinical Trials Network, National Institute on Drug Abuse, NIH, Bethesda, MD

The Clinical Trials Network (CTN) is an important program of the National Institute on Drug Abuse (NIDA) focused on the design and implementation of clinically relevant studies in the field of drug addiction treatment research. It consists of 17 geographically diverse “Nodes” centered in key academic institutions, partnering with local Community Treatment Programs (CTPs).

The objectives of the pre-conference session are:
1. Participants will learn how to use Buprenorphine in clinical settings including rapid detoxification, stabilization, and tapering from opioid addiction.
2. Participants will learn about the nature and extent of the problem of infectious diseases, especially Hepatitis C, and will learn innovative treatment approaches now being used in community treatment programs.
3. Participants will learn about using Buprenorphine and individual drug counseling to treat prescription opioid addicts including those with chronic pain.
4. Participants will learn about the availability of prescription drugs over the internet.

AGENDA
8:45 AM

Welcome & Introduction
Betty Tai, PhD
Director, Center for the Clinical Trials Network
National Institute on Drug Abuse, NIH
Bethesda, MD

Buprenorphine: Pharmacotherapy for Addiction

9:00 AM
Buprenorphine Opioid Detoxification Study Results: Treatment and Policy Implications
Walter Ling, MD
Principal Investigator, Pacific Region Node, NIDA CTN
Director, Integrated Substance Abuse Programs, Los Angeles, CA
Professor of Psychiatry and Biobehavioral Sciences, UCLA
Los Angeles, CA

9:40 AM
Buprenorphine Treatment in Pregnant Women
Hendree Jones, PhD
Associate Professor, Department of Psychiatry, JHU
Research Director, Center for Addiction & Pregnancy
Baltimore, MD

10:20 AM
Dissemination: Buprenorphine Awareness Package
Thomas Freese, PhD
Director, Pacific Southwest Addiction Technology Transfer Center (ATTC)
Los Angeles, CA

11:00 AM
Buprenorphine in the Community Setting
Allan J. Cohen, MA
Director of Research and Training
Bay Area Addiction Research and Treatment, Inc.
Los Angeles, CA

11:30 AM Lunch

Infectious Diseases: HCV Comorbidity

12:30 PM
HCV Infection: A Scientific View
David Thomas, MD
Associate Professor, Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD

1:10 PM
Policies: HCV Services in Substance Abuse Treatment
Lawrence Brown, MD
Senior Vice President, Addiction Research & Treatment Corporation
Clinical Associate Professor of Public Health, Weill Medical College, Cornell University
Immediate Past President, American Society of Addiction Medicine
Brooklyn, NY

1:50 PM
HCV Education: Improving Treatment
Diana Sylvestre, MD
Assistant Clinical Professor, Department of Medicine, University of California-San Francisco
Oakland, CA

2:30 PM
The Community Perspective
Paul McLaughlin, MA
Director, Hartford Dispensary
Hartford, CT

3:00 PM Break

Prescription Drugs: Abuse and Addiction

3:20 PM
The Availability of Controlled Substances Over the Internet
Robert F. Forman, PhD
Co-Principal Investigator, Delaware Valley Node, NIDA CTN
Assistant Professor, Department of Psychiatry, University of Pennsylvania, Treatment Research Center
Senior Investigator, Treatment Research Institute
Philadelphia, PA

4:00 PM
POATS: Treating Prescription Opioid Addiction
Jennifer Sharpe Potter, PhD
Research Director, Northern New England Node, NIDA CTN
Instructor in Psychology, Department of Psychiatry, Harvard Medical School
Belmont, MA

4:30 PM
Discussion
Petra Jacobs, MD
Medical Officer, Center for Clinical Trials Network
National Institute on Drug Abuse, NIH
Bethesda, MD

5:00 PM
Adjourn

Sponsored by The National Institute on Drug Abuse, The National Drug Abuse Treatment Clinical Trials Network (NIDA CTN).